MDT

95.97

-0.18%↓

136.48

+0.21%↑

VEEV

219.11

-1.79%↓

HQY

91.01

-0.55%↓

PHR.US

16.33

-3.37%↓

MDT

95.97

-0.18%↓

136.48

+0.21%↑

VEEV

219.11

-1.79%↓

HQY

91.01

-0.55%↓

PHR.US

16.33

-3.37%↓

MDT

95.97

-0.18%↓

136.48

+0.21%↑

VEEV

219.11

-1.79%↓

HQY

91.01

-0.55%↓

PHR.US

16.33

-3.37%↓

MDT

95.97

-0.18%↓

136.48

+0.21%↑

VEEV

219.11

-1.79%↓

HQY

91.01

-0.55%↓

PHR.US

16.33

-3.37%↓

MDT

95.97

-0.18%↓

136.48

+0.21%↑

VEEV

219.11

-1.79%↓

HQY

91.01

-0.55%↓

PHR.US

16.33

-3.37%↓

Home・Akciju saraksts・Smith & Nephew PLC ADR

Smith & Nephew PLC ADR

Atvērts

32.75 -0.15

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

32.42

Max

32.83

Galvenie mērījumi
By Trading Economics
Ienākumi	296M
Pārdošana	3B
P/E Sektora vidējais	29.589 88.032
Dividenžu ienesīgums	2.3
Peļņas marža	9.895
Darbinieki	17,000
EBITDA	723M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+8.96% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	2.30% 2.26%

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	14B
Iepriekšējā atvēršanas cena	32.9
Iepriekšējā slēgšanas cena	32.75

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

26.64 / 28.37 Atbalsts un pretestība

Smith & Nephew PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 31. dec. 22:20 UTC

Galvenie tirgus virzītāji

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

2025. g. 31. dec. 17:31 UTC

Galvenie tirgus virzītāji

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

2025. g. 31. dec. 16:30 UTC

Galvenie tirgus virzītāji

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

2025. g. 31. dec. 15:19 UTC

Galvenie tirgus virzītāji

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

2025. g. 31. dec. 15:17 UTC

Galvenie tirgus virzītāji

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

2025. g. 31. dec. 14:37 UTC

Galvenie tirgus virzītāji

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

2026. g. 1. janv. 23:35 UTC

Tirgus saruna

Gold Rises Amid Geopolitical Risks -- Market Talk

2026. g. 1. janv. 21:29 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope: Transaction Completed on Terms Agreed When Deal Announced on Nov 13

2026. g. 1. janv. 21:29 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope Sold Stake in JV to Tata Steel

2026. g. 1. janv. 21:28 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope Steel Says Sale of Stake in Tata BlueScope Steel Completed on Dec 31

2026. g. 1. janv. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 1. janv. 09:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 31. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 31. dec. 21:13 UTC

Iegādes, apvienošanās, pārņemšana

10 People to Watch in Wealth Management in 2026 -- Barrons.com

2025. g. 31. dec. 20:40 UTC

Tirgus saruna

Dollar Posting Its Worst Year Since 2017 -- Market Talk

2025. g. 31. dec. 20:22 UTC

Tirgus saruna

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

2025. g. 31. dec. 19:50 UTC

Tirgus saruna

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

2025. g. 31. dec. 19:31 UTC

Tirgus saruna

Precious Metals Cap Off Record Runs -- Market Talk

2025. g. 31. dec. 18:50 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 31. dec. 18:50 UTC

Tirgus saruna

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

2025. g. 31. dec. 17:17 UTC

Tirgus saruna

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

2025. g. 31. dec. 17:16 UTC

Galvenie tirgus virzītāji

OwlTing Climbs on Launch of $10M Stock-Buyback Program

2025. g. 31. dec. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 31. dec. 17:00 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

2025. g. 31. dec. 15:57 UTC

Iegādes, apvienošanās, pārņemšana

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

2025. g. 31. dec. 15:54 UTC

Tirgus saruna

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

2025. g. 31. dec. 15:02 UTC

Galvenie tirgus virzītāji

Nike Shares Rise After CEO Hill Buys $1M of Shares

2025. g. 31. dec. 14:40 UTC

Iegādes, apvienošanās, pārņemšana

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

2025. g. 31. dec. 14:20 UTC

Tirgus saruna

Crude Futures On Track to End the Year With Losses -- Market Talk

2025. g. 31. dec. 13:46 UTC

Tirgus saruna

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

Salīdzinājums

Cenas izmaiņa

Smith & Nephew PLC ADR Prognoze

Cenas mērķis

By TipRanks

8.96% augšup

Prognoze 12 mēnešiem

Vidējais 35.75 USD 8.96%

Augstākais 37.5 USD

Zemākais 34 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Smith & Nephew PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Smith & Nephew PLC ADR — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

26.64 / 28.37Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.